APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

Clinical trial NCT03655613 · TERMINATED

Trial details

NCT number: NCT03655613
Sponsor: Apollomics (Australia) Pty. Ltd.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Renal Cell Carcinoma

Start date: 2018-09-05
Primary completion: 2021-12-15
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.